Envafolimab
Advanced Malignant Solid Neoplasm
Yuanquan YangPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
123 Active assets in the Advanced Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib National Cancer Institute (NCI) | Phase 2 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 2 | BB |
Palbociclib National Cancer Institute (NCI) | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | B |
Carboplatin OHSU Knight Cancer Institute | Phase 2 | B |
View all 50 →
Same molecule, other indications
Envafolimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →